In 2024, Cell Impact entered into an agreement concerning flow plates, forming tools and fixtures with a European manufacturer, with a total contract value of SEK 18 million. Due to delays in the proj ...
Kista, Sweden - February 24, 2026 - Sivers Semiconductors AB (STO:SIVE), a global leader in photonics and wireless technologies, today announced the successful refinancing of all its existing, externa ...
19h
S.C. lawmakers consider mandatory labeling a shrimp catch’s country of origin following ‘Shrimpgate’
The South Carolina legislature is weighing a bill that would hit restaurateurs with a misdemeanor for misrepresenting the ...
Saab AB engages in the production and sale of products, services, and solutions for military defense, commercial aviation and civil security. It operates through the following segments: Aeronautics, ...
Just like the cars you see on the road, not all advanced highway driving assistance systems (AHD) are created equal. Some are better for commuting, some are better as long as you have your hands on ...
BBC Studios has announced the launch of BBC Nordic as a dedicated, on‑demand destination on SAS Airlines. Travellers on SAS ...
LONG BEACH, CA, UNITED STATES, February 24, 2026 /EINPresswire.com/ -- Ship & Shore Environmental, Inc. (S&SE), ...
European shares rose against a backdrop of broader market gains on Tuesday, tracking increased risk appetite on Wall Street, although investors awaited clarity on US trade policy after last week’s ...
Earlier this month, European Union leaders agreed to press ahead with a ‘Buy European’ policy to protect strategic sectors of the bloc’s industry, but in doing so they risk overlooking the critical ...
AMSTERDAM, Feb 24 (Reuters) - Axelera AI has secured $250 million in a funding round led by Innovation Industries that included BlackRock and SiteGround Capital as new investors, it said on Tuesday, ...
Construction Digital explores the leading Chief Construction Officers across the industry, celebrating those championing ...
NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results